Cardiometabolic Care™ by Epigenex Health™
Epigenex Health helps those accountable for population health improvements to prevent, mitigate, and manage cardiometabolic diseases (CMDs) using an epigenetically informed set of protocols and toolkits collectively known as Cardiometabolic Care.
Developed by three health industry pioneers, Epigenex Health Cardiometabolic Care serves population health decision-makers, care teams, and practice-based researchers.
The Company’s founders include:
- William H. Bestermann, Jr., MD, a practicing internist and practice-based medical researcher;
- Eric Kruep, PharmD, MSc, a tech-savvy PharmD and thought-leader in health economics, outcomes research, and market access strategies; and
- Synthia Laura Molina, BSc, MBA, a social-benefit strategist, corporate scalability pioneer, and breakthrough innovation expert.
Delivering new science, new systems, and new outcomes, Cardiometabolic Care includes three easy-to-adopt primary-care practice (PCP) protocols, three clinical-specialty protocols, and three practice-transformation toolkits–all supported by patient wraparound services.
The primary-care protocols target
- congestive heart failure (CHF),
- coronary artery disease and atherosclerosis, and
- hypertension, hyperlipidemia, pre-diabetes, and diabetes.
The clinical-specialty protocols target
- ophthalmic complications of diabetes;
- diabetic peripheral neuropathy, chronic kidney disease (CKD) and end-stage renal disease (ESRD); and
- myocardial infarctions (MIs/heart attacks) and strokes.
The practice-transformation toolkits include
- Cardiometabolic Care training programs,
- Cardiometabolic population health management services, and
- Cardiometabolic practice improvement solutions.
The protocols and toolkits dovetail with leading chronic condition management strategies to more reliably, efficiently, and effectively prevent, mitigate, and resolve cardiometabolic diseases (CMDs).
Cardiometabolic Care is an essential solution set under the healthcare industry’s volume-to-value (V2V) transition. The protocols and toolkits generate unprecedented improvements in economic, clinical, and humanistic outcomes (ECHOs).
Three cardiometabolic population health management initiatives underscored the ability of Cardiometabolic Care protocols and toolkits to support the elusive Triple/Quadruple Aim.
In each of these practice-based research programs, epigenetically informed CMD protocols and practice transformation toolkits
- reduced per capita costs,
- improved population health, and
- enhanced the experience of patients and providers.
The practice-based research populations included:
- A cohort of 89,034 Quality Blue Primary Care (QBPC) patients within Blue Cross Blue Shield of Louisiana’s 1.7+ million covered lives,
- 15,000 lives within a Fortune 500 self-insured employer’s (SIE’s) group health benefit, and
- 2,500 lives served by a community-based primary care practice (PCP).
Backed by primary and secondary research, Cardiometabolic Care‘s groundbreaking protocols and toolkits are safe, efficacious, and cost-effective.
Focusing in an unprecedented way on the epigenetic influences of a broad range of cardiometabolic stressors, Cardiometabolic Care (1) counters the influence of these dangerous stressors upstream and (2) mitigates their epigenetic effects downstream–targeting a largely overlooked stressor-related molecular signaling pathway that is remarkably shared by more than two-dozen chronic conditions.
By targeting this epigenetics-related metabolic common denominator—and by connecting the scientific dots between a range of life stressors and this adverse metabolic cascade—Cardiometabolic Care‘s unified protocols and toolkits are able to:
- simplify, integrate, and transform today’s dysfunctional, siloed approach to cardiometabolic disease management;
- enhance care quality for those with diabetes, hypertension, ischemic vascular disease, chronic kidney disease, and other dangerous cardiometabolic conditions; and
- improve performance, outcomes, and impacts.
Count on us to help you make meaningful progress around…
Lifestyle and Behavior Challenges
- Toxic Stress (e.g., from adverse childhood experiences, adverse cultural exposures, and adverse chemical effects [ACEs])
- Compulsive Overeating
- Smoking / Tobacco Use
- Drug Abuse
- Other Self-Care Challenges That Activate Deadly Metabolic Signaling
- Morbid Obesity
- High Cholesterol
- Sleep Apnea
- Other Precursors to Advanced Cardiometabolic Disease (CMD), Comorbidities, and Complications
- Type II Diabetes
- Diabetic Peripheral Neuropathy
- Diabetic Retinopathy
- Chronic Kidney Disease (CKD)
- Kidney Transplant
Ischemic Vascular Disease
- Congestive Heart Failure
- Coronary Artery Disease
- Cerebrovascular Disease
- Peripheral Arterial Disease
- Atrial Fibrillation
- Ventricular Arrhythmia
- Left Ventricular Hypertrophy
- Transient Ischemic Attack
- Heart Attack
- Heart Transplant
- Liver Transplant
While our unified, stressor-mitigating upstream protocols and toolkits and our unified, disease-mitigating downstream protocols and toolkits are gaining mainstream buy-in, we continue to welcome partnerships with progressive health industry stakeholders committed to measurably reducing the incidence, prevalence, and cost of cardiometabolic conditions.
In an era of performance, outcomes, and impact accountability, our protocols and toolkits are a “must have.” They offer an unprecedented return on investment (ROI) to organizations that carry non-transferrable financial and human capital risks in relation to cardiometabolic diseases (CMDs).
Organizations that benefit most include:
- Onsite and Near-Site Clinics (e.g., Worksite Clinics, Patient-Centered Medical Homes, and SuperClinics)
- Self-Insured Employers and Unions
- Accountable Care Organizations (ACOs)
- Medicare Advantage Programs
- Medicaid Managed Care Programs
- Veterans Affairs (VA) and Department of Defense (DoD) Programs
- Federally Qualified Health Centers (FQHCs)
Reflecting on prior studies using optimal medical therapy (OMT), our shared goal with pioneering partners is to further document the 360-degree impact associated with the application of our molecular medical management (MMM) and patient wraparound services on heart attacks and other high-cost, high-risk conditions.
For example, we seek to document cost savings beyond the Kaiser Permanente’s already-demonstrated $21,900 per patient per year (PPPY) savings threshold for optimal medical therapy (OMT), with greater than tenfold reductions in mortality.
Count on us to empower primary care practices (PCPs) and performance-accountable, outcomes-accountable, and impact-accountable specialty practices while reducing the clinical, administrative, and financial risks associated with cardiometabolic diseases (CMDs) and other chronic conditions.
Together, we can reduce the incidence, prevalence, and cost of cardiometabolic disease (CMD).